Following its first Chinese approval earlier this year, a next generation BTK blocker, Calquence (acalabrutinib), has picked up another nod in the country.
Developed by Britain’s AstraZeneca (LSE: AZN), the product has been approved by the National Medical Products Administration (NMPA) for use against certain forms of blood cancer.
Adults who have received at least one prior therapy for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) will be eligible for treatment with the drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze